0.4838
전일 마감가:
$0.4912
열려 있는:
$0.49
하루 거래량:
1.68M
Relative Volume:
0.58
시가총액:
$74.52M
수익:
-
순이익/손실:
$-111.13M
주가수익비율:
-0.3665
EPS:
-1.32
순현금흐름:
$-91.53M
1주 성능:
+5.59%
1개월 성능:
-24.69%
6개월 성능:
-76.74%
1년 성능:
-88.77%
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
명칭
Tenaya Therapeutics Inc
전화
415-865-2066
주소
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
TNYA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
TNYA
Tenaya Therapeutics Inc
|
0.4838 | 74.52M | 0 | -111.13M | -91.53M | -1.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
496.49 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.86 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
620.97 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
254.85 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
249.46 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-06-10 | 개시 | William Blair | Outperform |
2023-11-30 | 개시 | Leerink Partners | Outperform |
2022-06-15 | 개시 | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
H.C. Wainwright maintains Buy on Tenaya Therapeutics stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Tenaya Therapeutics stock - Investing.com
Tenaya reports progress in ARVC gene therapy study - Investing.com
Tenaya Therapeutics Presents Interim Data from RIDGE™ - GlobeNewswire
Major Breakthrough: 175-Patient ARVC Study Shows 93% Could Benefit from New Gene Therapy Treatment - Stock Titan
Tenaya Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Tenaya Therapeutics faces Nasdaq delisting over share price - Investing.com Australia
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - The Manila Times
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com
Tenaya highlights HCM gene therapy interim data at ACC 2025 - Yahoo Finance
Tenaya to lay off about one-third of staff, reveals heart gene therapy data - Endpoints News
Top 3 Insider Stock Buys in March-Are They Still Good in April? - MSN
Tenaya Therapeutics Announces Late Breaker Presentation - GlobeNewswire
Revolutionary Gene Therapy Transforms Severe Heart Disease Patients in Landmark Trial - Stock Titan
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting - The Manila Times
Undervalued Cardiology Stocks to Watch: TNYA, MIST, BBIO, ALNY - GuruFocus
Tenaya Therapeutics IncOn Mar 27, Co Approves Restructuring PlanSEC Filing - MarketScreener
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March? - MSN
FY2025 Earnings Estimate for TNYA Issued By Chardan Capital - Defense World
Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March - Yahoo
Top 3 Insider Stock Buys in March—Are They Still Good in April? - Benzinga
Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function - Yahoo Finance
15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey
Breakeven On The Horizon For Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - simplywall.st
Tenaya reports promising gene therapy for heart condition By Investing.com - Investing.com South Africa
Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial - MarketScreener
Tenaya reports promising gene therapy for heart condition - Investing.com India
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy - Yahoo
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models - GlobeNewswire
Revolutionary Heart Disease Treatment: Gene Therapy Reverses Cardiac Damage in Landmark Study - Stock Titan
Tenaya Therapeutics announces $300M mixed shelf offering; shares down - MSN
Tenaya Therapeutics files for mixed shelf offering of up to $300 mln -March 21, 2025 at 04:16 pm EDT - MarketScreener
Insiders Are Spending Big: 15 Stocks Leading in March - Insider Monkey
Tenaya Therapeutics to Present New Data on MYBPC3-Associated Hypertrophic Cardiomyopathy at ACC 2025 Annual Scientific Session - Nasdaq
Tenaya Therapeutics Announces Late Breaker and New Data - GlobeNewswire
Major Breakthrough: Tenaya's Gene Therapy Trial Reveals Critical One-Year Heart Disease Data - StockTitan
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session - Yahoo Finance
Canaccord Genuity Group Lowers Tenaya Therapeutics (NASDAQ:TNYA) Price Target to $6.00 - Defense World
Analysts Issue Forecasts for TNYA Q1 Earnings - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Morgan Stanley Has Lowered Expectations for Tenaya Therapeutics (NASDAQ:TNYA) Stock Price - Defense World
Tenaya Therapeutics Inc (TNYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):